Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000307909
Ethics application status
Approved
Date submitted
16/03/2011
Date registered
23/03/2011
Date last updated
23/03/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Paclitaxel and Epirubicin as neoadjuvant systemic treatment for locally advanced breast cancer
Query!
Scientific title
A phase II study of Paclitaxel and Epirubicin, as neoadjuvant systemic treatment, for women with locally advanced breast cancer to assess response rates
Query!
Secondary ID [1]
259795
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast cancer
261380
0
Query!
Condition category
Condition code
Cancer
259535
259535
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Neoadjuvant chemotherapy with Paclitaxel and Epirubicin.
Schedule: Paclitaxel 175mg per m2 intravenously, Epirubicin 90mg per m2, intravenously given once every 3 weeks for a total of 4 doses before surgery ( total of 12 weeks of treatment)
Query!
Intervention code [1]
264230
0
Treatment: Drugs
Query!
Comparator / control treatment
nil
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
262342
0
Response rates- to be assessed clinically and radiologically ( CT scan) before surgery. Also pathological response rates to be assessed after surgery.
Query!
Assessment method [1]
262342
0
Query!
Timepoint [1]
262342
0
16 weeks
Query!
Secondary outcome [1]
273583
0
Tolerance- to be assessed by blood tests ( Hemogram. biochemistry) and clinical examination ( Physical examination/ radiology)
Query!
Assessment method [1]
273583
0
Query!
Timepoint [1]
273583
0
3 weeks - tolerance will be assesed before start of each course of chemotherapy. If the patient presents with symptoms before this then they will be assessed on presentation.
Query!
Secondary outcome [2]
273590
0
Disease free survival. This will be assessed by 3 monthly for the for the first 2 years and 6 monthly for the next 3 years. Tests will involve CT scan and blood tests at every visit and mammogram of the contralateral breast every 12 months.
Query!
Assessment method [2]
273590
0
Query!
Timepoint [2]
273590
0
3 months
Query!
Secondary outcome [3]
273591
0
Overall Survival
Follow up visits will be 3 monthly for the for the first 2 years and 6 monthly for the next 3 years. Death due to nay cause will be recorded and analysed for survival.
Query!
Assessment method [3]
273591
0
Query!
Timepoint [3]
273591
0
3 months
Query!
Eligibility
Key inclusion criteria
Women aged 18 years or over with histological or cytologically confirmed locally advanced breast cancer. T3-4 Nx, Tx N2-3
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Presence of metastatic disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Open label Phase II study
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Non randomised
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
16/08/2004
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
264680
0
Hospital
Query!
Name [1]
264680
0
The Queen Elizabeth Hospital
Query!
Address [1]
264680
0
Medical Oncology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville , SA 5011
Query!
Country [1]
264680
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Queen Elizabeth Hospital
Query!
Address
Medical Oncology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville , SA 5011
Query!
Country
Australia
Query!
Secondary sponsor category [1]
263815
0
Commercial sector/Industry
Query!
Name [1]
263815
0
Bristol-Myers Squibb
Query!
Address [1]
263815
0
Bristol Myers Squibb Pharmaceuticals
Medical Department ,PO Box 39,Noble Park Vic 3174
Query!
Country [1]
263815
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
266673
0
The Queen Elizabeth hospital ethics comittee
Query!
Ethics committee address [1]
266673
0
The Queen Elizabeth Hospital, 28 Woodville Road, Woodville , SA 5011
Query!
Ethics committee country [1]
266673
0
Australia
Query!
Date submitted for ethics approval [1]
266673
0
20/05/2004
Query!
Approval date [1]
266673
0
26/05/2004
Query!
Ethics approval number [1]
266673
0
2004059
Query!
Summary
Brief summary
This study is looking at the combination of the drugs Paclitaxel and Epirubicin used as neoadjuvant systemic treatment for women with locally advanced breast cancer in order to assess response rates
Who is it for?
You may take part in this study if you are a female aged 18 years or over and have a confirmed diagnosis of locally advanced breast cancer (cancer that is considered inoperable by your treating surgeon).
Trial Details
Participants in this study will receive Neoadjuvant (before surgery) chemotherapy with Paclitaxel and Epirubicin. The schedule of treatment will involve the drug Paclitaxel given at a dose of 175mg per m2 intravenously, and Epirubicin 90mg per m2 given intravenously given once every 3 weeks for a total of 4 doses before surgery (and an overall total of 12 weeks of treatment)
The aim of this study is to see how a combination of 2 chemotherapeutic drugs - Paclitaxel and Epirubicin, is tolerated in women with locally advanced breast cancer. We also expect to see how effective this combination is in the treatment of this condition.
Query!
Trial website
Nil
Query!
Trial related presentations / publications
N/A
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32350
0
Query!
Address
32350
0
Query!
Country
32350
0
Query!
Phone
32350
0
Query!
Fax
32350
0
Query!
Email
32350
0
Query!
Contact person for public queries
Name
15597
0
Dr Kenneth Pittman
Query!
Address
15597
0
Medical Oncology, The Queen Elizabeth hospital, 28 Woodville Road, Woodville, SA 5011
Query!
Country
15597
0
Australia
Query!
Phone
15597
0
+61 882226000
Query!
Fax
15597
0
Query!
Email
15597
0
[email protected]
Query!
Contact person for scientific queries
Name
6525
0
Dr Kenneth Pittman
Query!
Address
6525
0
Medical Oncology, The Queen Elizabeth hospital, 28 Woodville Road, Woodville, SA 5011
Query!
Country
6525
0
Australia
Query!
Phone
6525
0
+61 882226000
Query!
Fax
6525
0
Query!
Email
6525
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF